Other

Christian-Albrechts-Universitaet Zu Kiel

Christian-Albrechts-Universitat Zu Kiel

Dritte Patentportfolio Beteiligungsgesellschaft Mbh &Co. Kg

Wilex Ag

Gruenenthal Gmbh

Christian-Albrechts-University of Kiel

Dritte Patentportfolio Beteiligungsgesellschaft Mgh & Co. Kg

Develco Pharma Schweiz Ag

Bernd Clement

Dennis Schade

Jürke Kotthaus

Dieter Heber

Joscha Kotthaus

Stefan Sperl

Katja Wosikowski

Markus Buergle

Wolfgang Schmalix

Ullvi Bluhm

Christiane Wolter-Reeh

Helen Schenk

Christopher Meier

Bernd Sundermann

Hagen-Heinrich Hennies

Helmut Buschmann

Tamara Natalie Steinhauer

Uwe Buss

Friederike Friedrich-Harder

Ulrich Wolschendorf

Matthias Weide

Franz Furkert

Lars Stenzel

Juerke Kotthaus

Britta Gerig

Markus BÜRGLE

Friederike Friedrich

Christiane Reeh

Helen Hungeling

The invention relates to novel pyrido-phenanthroline derivatives, to the production and use thereof in the field of medicine, in particular for cancer therapy.

Pyrido-phenanthroline derivatives, production and use thereof as medicaments

The invention relates to oseltamivir derivatives as influenza neuraminidase inhibitors for treating influenza infections and to a method for producing said compounds.

Compounds for the treatment of influenza

The invention relates to the use of a substance of the general form (I) to produce an antibacterial and/or antifungal drug, wherein X is a methylene group or a carbonyl group; R, R, and Rare each selected from the group comprising hydrogen, an alkyl group having a chain length of 1-4 carbon atoms, an alkoxy group having a chain length of 1-3 carbon atoms, and a halogen; Rand Rare each selected from the group comprising hydrogen and an alkyl group having a chain length of 1-4 carbon atoms; and n=3 to 6. 

Antibacterial and antifungal biphenylyl compounds

The present invention relates to prodrug derivatives of pentamidine, their use in the treatment and/or prophylaxis of diseases such as tumor diseases, as well as leishmaniasis, trypanosomiasis, pneumocystis carinii pneumonia (PcP), and malaria.

Orally bioavailable pentamidine prodrugs for the treatment of diseases

The present invention relates to physically-chemically and pharmacokinetically enhanced N-hydroxy-L-arginine (NOHA) derivatives and a method for producing the NOHA derivatives having enhanced physical-chemical and pharmacokinetic properties according to the invention.

[object Object]

The invention relates to a method for improving the bioavailability of pharmaceutical substances and for allowing the pharmaceutical substances to permeate the blood-brain barrier, the pharmaceutical substances having at least one or more amidine, guanidine, N-hydroxyamidine (amidoxime) or N-hydroxyguanidine functions. The invention also relates to medicaments containing the correspondingly modified pharmaceutical substances.

Method for producing prodrug from amidoxime and N-hydroxyguanidine carboxylic acid esters

New phenanthroline derivatives as drug as well as methods for producing said compounds are provided.

Pyrido [3,4-C] [1,9] phenanthroline and 11, 12 dihydropyrido [3,4-C] [1,9] phenanthroline derivatives and the use thereof, particularly for treating cancer

The invention relates to an inhibitor of dimethylarginine dimethylaminohydrolase (DDAH) of general structural formula (I), wherein B is a branched or unbranched, substituted or non-substituted, saturated or unsaturated hydrocarbon chain having a chain length of 1 to 6 and/or a substituted or non-substituted aromatic system having a ring size of 3 to 6; Ris selected from the group of structures (i-vii), wherein R, Rand Rare selected from the group consisting of hydrogen, an alkyl or aryl radical, Rand Rare selected from the group consisting of hydrogen, a hydrocarbon chain having a chain length of 1 to 8 and an aryl radical, R, R, Rand Rare selected from the group consisting of hydrogen, and alkyl or aryl radical; W is oxygen (O) or nitrogen (N); and X is a methylene group (CH) or a secondary amino group (NH); Y is a branched or unbranched, substituted or non-substituted, saturated or unsaturated hydrocarbon chain having a chain length of 1 to 6 and/or a substituted or non-substituted aromatic system having a ring size of 3 to 6; Z is hydrogen (H) or a methoxyl group; and the radical (B) carrying the amino group has no carboxyl group.

Inhibitors of dimethylarginine dimethylaminohydrolase

The present invention relates to prodrug derivatives of dabigatran, their use in the treatment and/or prophylaxis of diseases, in particular thrombotic diseases, stroke, cardiac infarction and/or atrial fibrillation and cardiac arrhythmia, as well as oncological diseases of any pathogenesis.

Orally bioavailable dabigatran prodrugs for the treatment of diseases

The invention relates to a method for improving bioavailability of pharmaceutical substances and for allowing the pharmaceutical substances to permeate the blood-brain barrier, the pharmaceutical substances having at least one or more amidine, guanidine, N-hydroxyamidine (amidoxime) or N-hydroxyguanidine functions. The invention also relates to medicaments containing the correspondingly modified pharmaceutical substances.

Amino acid derivatives used as pharmaceutical substances

Use of the substance characterized by general structural formula (I) for the preparation of an agent inhibiting the enzymatic activity of NO-synthase, R1, R2, R3, R4 and/or R5 being hydrogen, an alkyl group, an aryl group or a heterocyclic group and n equals 2 or 3.

Basic acetophenones as inhibitors of NO-synthases

The present invention relates to novel compounds for inhibiting the urokinase plasminogen activator (uPA), which have high bioavailability and oral administerability, and also to the use thereof as therapeutic active compounds for the treatment of urokinase- or/and urokinase receptor-associated disorders such as, for example, tumors and metastasizing. The invention relates in particular to compounds containing hydroxyamidine or hydroxyguanidine groups.

Hydroxyamidine and hydroxyguanidine compounds as urokinase inhibitors

The invention relates to substituted pyrido[1,2-a]pyrimidine compounds corresponding to formula (I) wherein:

Substituted pyrido(1,2-a)pyrimidines and their use as NOS inhibitors

The invention relates to novel phenanthridine derivatives and to medicaments, which are for use in antitumoral therapy and prophylaxis and which contain these phenanthridine derivatives. It could be shown that up to now specifically substituted phenanthridine derivatives of the prior art neither have a known nor an antitumoral activity that is to be expected.

Growing community of inventors

Kiel, Germany

Bernd Clement